In line with this, one study in a melanoma model has shown that expansion and activation of TIDCs at the tumor site by recruiting and activating agents such as FLT3L and poly I:C, enhanced therapeutic response to immune checkpoint inhibitors (196). Here, FLT3LG is linked to neoplasm.